NDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
6/8 — Strong
COZAAR (losartan potassium) by Merck & Co. is [formed from angiotensin i in a reaction catalyzed by angiotensin converting enzyme (ace, kininase ii)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. Approved for hypertension. First approved in 1995.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COZAAR (losartan potassium) is an oral angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and aldosterone secretion. It is indicated for hypertension, diabetic nephropathy, stroke prevention in hypertensive patients, and heart failure with left ventricular hypertrophy. The drug works by competitively inhibiting angiotensin II binding, with its active metabolite being 10-40 times more potent than the parent compound.
$5MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with limited Part D claims, indicating significant generic competition and shrinking branded opportunity.
Mechanism of Action
[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…
Indications (1)
Worked on COZAAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.